[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE531358T1 - Selbsterhaltende wässrige pharmazeutische zusammensetzungen - Google Patents

Selbsterhaltende wässrige pharmazeutische zusammensetzungen

Info

Publication number
ATE531358T1
ATE531358T1 AT07842914T AT07842914T ATE531358T1 AT E531358 T1 ATE531358 T1 AT E531358T1 AT 07842914 T AT07842914 T AT 07842914T AT 07842914 T AT07842914 T AT 07842914T AT E531358 T1 ATE531358 T1 AT E531358T1
Authority
AT
Austria
Prior art keywords
self
pharmaceutical compositions
aqueous pharmaceutical
supporting aqueous
supporting
Prior art date
Application number
AT07842914T
Other languages
English (en)
Inventor
Bhagwati P Kabra
Masood A Chowhan
L Wayne Schneider
Wesley Wehsin Han
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE531358(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Application granted granted Critical
Publication of ATE531358T1 publication Critical patent/ATE531358T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07842914T 2006-09-21 2007-09-20 Selbsterhaltende wässrige pharmazeutische zusammensetzungen ATE531358T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82652906P 2006-09-21 2006-09-21
US82741106P 2006-09-28 2006-09-28
PCT/US2007/079082 WO2008036847A2 (en) 2006-09-21 2007-09-20 Self preserved aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE531358T1 true ATE531358T1 (de) 2011-11-15

Family

ID=39156274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07842914T ATE531358T1 (de) 2006-09-21 2007-09-20 Selbsterhaltende wässrige pharmazeutische zusammensetzungen

Country Status (22)

Country Link
US (3) US8268299B2 (de)
EP (1) EP2068822B2 (de)
JP (2) JP4785970B2 (de)
KR (1) KR101021933B1 (de)
AR (1) AR062929A1 (de)
AT (1) ATE531358T1 (de)
AU (1) AU2007299727B2 (de)
BR (1) BRPI0717067A2 (de)
CA (1) CA2606370C (de)
CL (1) CL2007002705A1 (de)
CY (1) CY1112138T1 (de)
DK (1) DK2068822T4 (de)
ES (1) ES2374444T5 (de)
HK (1) HK1126667A1 (de)
MX (1) MX2009002221A (de)
PL (1) PL2068822T5 (de)
PT (1) PT2068822E (de)
RU (1) RU2436568C2 (de)
SI (1) SI2068822T2 (de)
TW (1) TWI394564B (de)
UY (1) UY30605A1 (de)
WO (1) WO2008036847A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
BRPI0717093A2 (pt) 2006-09-28 2013-11-26 Alcon Res Ltd Composições farmacêuticas aquosas autopreservadas
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
EP2420223B1 (de) † 2008-03-17 2017-07-19 Novartis Ag Wässrige pharmazeutische Zusammensetzungen mit Borat-Polyol-Komplexen
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
MX2011005586A (es) * 2008-12-22 2011-06-20 Alcon Res Ltd Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo.
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
KR20190049931A (ko) * 2009-12-15 2019-05-09 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 무자극성 안과용 포비돈-요오드 조성물
TW201127423A (en) * 2009-12-17 2011-08-16 Alcon Res Ltd Ophthalmic solutions with improved disinfection profiles
LT2680832T (lt) 2011-03-04 2019-10-25 Gruenenthal Gmbh Tapentadolio vandeninė farmacinė kompozicija, skirta vartoti geriant
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
JP6150510B2 (ja) * 2011-12-12 2017-06-21 ロート製薬株式会社 眼科用水性組成物
EP2630952A1 (de) 2012-02-23 2013-08-28 Novagali Pharma S.A. Selbstkonservierende Öldispersionen enthaltend Borsäure
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
US20150374820A1 (en) * 2013-02-15 2015-12-31 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing zinc
RU2015142245A (ru) 2013-03-13 2017-04-18 Кур Фармасьютикалз Дивелопмент Компани Иммуномодифицирующие частицы для лечения воспаления
EP3037094A1 (de) 2014-12-23 2016-06-29 Poifa Warszawa SA Ophthalmische pharmazeutische Zusammensetzung
BR112017018569A2 (pt) 2015-03-27 2018-04-24 Gruenenthal Gmbh formulação estável para administração parentérica de tapentadol
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
JP7160799B2 (ja) 2016-09-23 2022-10-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与用安定製剤
WO2019123266A1 (en) 2017-12-20 2019-06-27 Novartis Ag Ophthalmic composition having a prostaglandin and a beta-blocker
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
US20220031739A1 (en) * 2020-07-31 2022-02-03 Eye Therapies Llc Anti-viral compositions and methods of use thereof
WO2023054669A1 (ja) 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物
WO2024003078A1 (en) * 2022-06-27 2024-01-04 Warszawskie Zaklady Farmaceutyczne Polfa Sa Preservative-free ophthalmic composition comprising a prostaglandin analogue
EP4309644A1 (de) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Konservierungsfreie ophthalmische zusammensetzung, die ein antiglaukommittel umfasst

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2084870B (en) * 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
CA2098299C (en) * 1990-12-27 1997-05-20 Mary Mowrey-Mckee Method and composition for disinfecting contact lenses
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
DE69333850T3 (de) * 1992-05-06 2011-03-17 Alcon Laboratories, Inc., Fort Worth Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5320843A (en) * 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (de) 1993-11-12 1996-04-21 Ciba Geigy Ag
AU3070395A (en) * 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US6024954A (en) * 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
EP0817607A1 (de) * 1995-03-20 1998-01-14 Unilever Plc Flüssige reinigunsmittel zusammensetzungen
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
WO1998011867A1 (en) * 1996-09-20 1998-03-26 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
CN1157227C (zh) * 1996-12-13 2004-07-14 阿尔康实验室公司 低分子量氨基醇在眼用组合物中的应用
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
DE69818675T2 (de) * 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
US6034043A (en) * 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CN1477929A (zh) * 2000-11-29 2004-02-25 ��˹��ŵ�� 水性消毒系统
AR035509A1 (es) * 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP2004339104A (ja) * 2003-05-14 2004-12-02 Rohto Pharmaceut Co Ltd 溶液の安定化方法
ES2323132T3 (es) * 2003-12-09 2009-07-07 Alcon, Inc. Uso de bis-aminas para incrementar la actividad antimicrobiana de composiciones acuosas.
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
JP2007513952A (ja) * 2003-12-11 2007-05-31 アルコン、インコーポレイテッド 多糖／ホウ酸塩ゲル化系を含む眼用組成物
US20050214382A1 (en) * 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物

Also Published As

Publication number Publication date
DK2068822T4 (da) 2022-10-31
EP2068822B2 (de) 2022-07-27
HK1126667A1 (en) 2009-09-11
CA2606370C (en) 2012-03-27
ES2374444T3 (es) 2012-02-16
DK2068822T3 (da) 2012-01-23
KR20090058567A (ko) 2009-06-09
US8268299B2 (en) 2012-09-18
JP2010504358A (ja) 2010-02-12
PL2068822T3 (pl) 2012-03-30
SI2068822T2 (sl) 2022-10-28
CA2606370A1 (en) 2008-03-21
JP4785970B2 (ja) 2011-10-05
BRPI0717067A2 (pt) 2013-09-24
KR101021933B1 (ko) 2011-03-16
PT2068822E (pt) 2012-01-10
EP2068822A2 (de) 2009-06-17
UY30605A1 (es) 2008-03-31
US8323630B2 (en) 2012-12-04
AU2007299727B2 (en) 2011-10-06
TW200820962A (en) 2008-05-16
CL2007002705A1 (es) 2008-05-16
SI2068822T1 (sl) 2012-02-29
US20080075790A1 (en) 2008-03-27
AR062929A1 (es) 2008-12-17
MX2009002221A (es) 2009-03-13
EP2068822B1 (de) 2011-11-02
AU2007299727A8 (en) 2009-04-09
JP5411897B2 (ja) 2014-02-12
ES2374444T5 (es) 2022-11-21
TWI394564B (zh) 2013-05-01
US20110195132A1 (en) 2011-08-11
RU2436568C2 (ru) 2011-12-20
WO2008036847A3 (en) 2008-05-29
CY1112138T1 (el) 2015-11-04
RU2009114849A (ru) 2010-10-27
PL2068822T5 (pl) 2022-11-14
WO2008036847A2 (en) 2008-03-27
US20130053440A1 (en) 2013-02-28
JP2011246476A (ja) 2011-12-08
AU2007299727A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
ATE531358T1 (de) Selbsterhaltende wässrige pharmazeutische zusammensetzungen
LTPA2018005I1 (lt) Farmacinė kompozicija
DK2399579T3 (da) Farmaceutiske doseringsformer
BRPI0715712A2 (pt) Composição farmacêutica
ATE532788T1 (de) Pharmazeutische verbindungen
BRPI0719393A2 (pt) Composição farmacêutica
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
RU2398586C3 (ru) Фармацевтическая композиция
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
NO20075628L (no) Farmasøytiske formuleringer
ATE493119T1 (de) Pharmazeutische zusammensetzung
NO20090578A (no) Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0721651A2 (pt) Composição farmacêutica
DK2063868T3 (da) Farmaceutiske sammensætninger indeholdende rosuvastatin-calcium
DK1957073T3 (da) Lægemiddel
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0820198A2 (pt) composições farmacêuticas
ATE480227T1 (de) Pharmazeutische zusammensetzungen mit quetiapinfumarat
ATE530164T1 (de) Wässrige pharmazeutische zubereitung
DK2001445T3 (da) Farmaceutiske sfæroider
IS8587A (is) Atorvastatin lyfjasamsetning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2068822

Country of ref document: EP